Cheapest GLP-1 Receptor Agonist
Based on the most recent 2024-2025 pricing data, exenatide (immediate-release, 10 mcg pen) is the least expensive GLP-1 receptor agonist at $771 NADAC (National Average Drug Acquisition Cost) per month for the maximum approved daily dose of 20 mg (administered as 10 mcg twice daily). 12
Cost Comparison of Available GLP-1 RAs
Using the most current 2024-2025 guideline pricing data 22:
Monthly NADAC costs (most accurate real-world acquisition costs):
- Exenatide 10 mcg pen (twice daily): $818 - Cheapest option
- Exenatide ER 2 mg pen (weekly): $1,101
- Liraglutide 1.8 mg pen (daily): $1,077
- Dulaglutide 4.5 mg pen (weekly): $941
- Semaglutide 2 mg pen (weekly): $933
- Semaglutide 14 mg tablet (daily): $933
Tirzepatide (dual GIP/GLP-1 agonist): $1,030 - Most expensive
Important Clinical Considerations
Why NADAC Matters Over AWP
The NADAC pricing reflects actual pharmacy acquisition costs and is more representative of real-world expenses than Average Wholesale Price (AWP), which tends to overestimate actual costs 11. The 2024 data shows NADAC is consistently 15-25% lower than AWP across all GLP-1 agents.
Cost vs. Clinical Benefit Trade-offs
While exenatide is cheapest, newer agents like semaglutide and tirzepatide demonstrate superior weight loss and potentially greater cardiovascular benefits 3. The cost-effectiveness analysis shows that:
- GLP-1 RAs are LOW value as first-line monotherapy (high certainty of evidence) 4
- GLP-1 RAs may be INTERMEDIATE value when added to metformin compared to adding nothing (low certainty of evidence) 4
- Newer, more expensive agents show better persistence and outcomes in cardiovascular disease populations 3
Practical Prescribing Algorithm
For cost-constrained patients without established cardiovascular disease:
- Start with exenatide 10 mcg twice daily ($818/month NADAC)
- If twice-daily dosing is problematic, consider exenatide ER weekly ($1,101/month)
- If gastrointestinal side effects are intolerable, escalate to dulaglutide or semaglutide
For patients with established ASCVD or high cardiovascular risk:
- Prioritize semaglutide or dulaglutide despite higher cost, as these have proven cardiovascular outcome benefits 31
- The cardiovascular risk reduction may justify the additional $100-150/month cost
Common Pitfalls
- Don't assume all GLP-1 RAs are equally expensive - there's a 35% cost difference between cheapest and most expensive options
- Beware of insurance formulary restrictions - many plans preferentially cover specific agents regardless of list price
- Account for dosing frequency - twice-daily exenatide may have lower adherence despite lower cost
- Consider total diabetes medication costs - adding a GLP-1 RA to metformin ($2-5/month NADAC) 12 is still substantially more expensive than traditional oral agents
Real-World Cost Burden
Recent data shows that nearly one in five (18.18%) GLP-1 users experience high out-of-pocket burden (≥10% of household income), with highest burden among uninsured and low-income adults 5. Median annual per-capita out-of-pocket spending was $1,528 across all GLP-1 agents 5.